
Hussein Daoud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11715930/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	De Novo Mutations in Moderate or Severe Intellectual Disability. PLoS Genetics, 2014, 10, e1004772.	3.5	364
2	Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nature Reviews Genetics, 2009, 10, 769-782.	16.3	321
3	Excess of De Novo Deleterious Mutations in Genes Associated with Glutamatergic Systems in Nonsyndromic Intellectual Disability. American Journal of Human Genetics, 2011, 88, 306-316.	6.2	310
4	Direct Measure of the De Novo Mutation Rate in Autism and Schizophrenia Cohorts. American Journal of Human Genetics, 2010, 87, 316-324.	6.2	222
5	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nature Communications, 2016, 7, 11253.	12.8	174
6	Deleterious mutations in the essential mRNA metabolism factor, hGle1, in amyotrophic lateral sclerosis. Human Molecular Genetics, 2015, 24, 1363-1373.	2.9	122
7	A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in <i>C9orf72</i> reveals marked differences in results among 14 laboratories. Journal of Medical Genetics, 2014, 51, 419-424.	3.2	118
8	Recent advances in the genetics of amyotrophic lateral sclerosis. Current Neurology and Neuroscience Reports, 2009, 9, 198-205.	4.2	103
9	Exome sequencing reveals SPG11 mutations causing juvenile ALS. Neurobiology of Aging, 2012, 33, 839.e5-839.e9.	3.1	87
10	Next-generation sequencing for diagnosis of rare diseases in the neonatal intensive care unit. Cmaj, 2016, 188, E254-E260.	2.0	86
11	ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiology of Aging, 2017, 51, 178.e1.178.e9.	3.1	86
12	Association of Long ATXN2 CAG Repeat Sizes With Increased Risk of Amyotrophic Lateral Sclerosis. Archives of Neurology, 2011, 68, 739-42.	4.5	80
13	Identification of rare protein disulfide isomerase gene variants in amyotrophic lateral sclerosis patients. Gene, 2015, 566, 158-165.	2.2	70
14	Resequencing of 29 Candidate Genes in Patients With Familial and Sporadic Amyotrophic Lateral Sclerosis. Archives of Neurology, 2011, 68, 587-93.	4.5	52
15	Identification of a pathogenic <i>FTO</i> mutation by next-generation sequencing in a newborn with growth retardation and developmental delay. Journal of Medical Genetics, 2016, 53, 200-207.	3.2	50
16	Analysis of OPTN as a causative gene for amyotrophic lateral sclerosis. Neurobiology of Aging, 2011, 32, 555.e13-555.e14.	3.1	43
17	Case report of novel DYRK1A mutations in 2 individuals with syndromic intellectual disability and a review of the literature. BMC Medical Genetics, 2016, 17, 15.	2.1	42
18	UBQLN2 mutations are rare in French and French–Canadian amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 2230.e1-2230.e5.	3.1	40

HUSSEIN DAOUD

#	Article	IF	CITATIONS
19	Mutation analysis of PFN1 in familial amyotrophic lateral sclerosis patients. Neurobiology of Aging, 2013, 34, 1311.e1-1311.e2.	3.1	31
20	Analysis of the UNC13A Gene as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis. Archives of Neurology, 2010, 67, 516-7.	4.5	28
21	Reinterpretation of sequence variants: one diagnostic laboratory's experience, and the need for standard guidelines. Genetics in Medicine, 2018, 20, 365-368.	2.4	28
22	Data sharing as a national quality improvement program: reporting on BRCA1 and BRCA2 variant-interpretation comparisons through the Canadian Open Genetics Repository (COGR). Genetics in Medicine, 2018, 20, 294-302.	2.4	27
23	C9orf72 Hexanucleotide Repeat Expansions as the Causative Mutation for Chromosome 9p21–Linked Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Archives of Neurology, 2012, 69, 1159-63.	4.5	22
24	Exome sequencing identifies recessive CDK5RAP2 variants in patients with isolated agenesis of corpus callosum. European Journal of Human Genetics, 2016, 24, 607-610.	2.8	22
25	Investigation of C9orf72 repeat expansions in Parkinson's disease. Neurobiology of Aging, 2013, 34, 1710.e7-1710.e9.	3.1	21
26	Detailed Biochemical and Bioenergetic Characterization of FBXL4-Related Encephalomyopathic Mitochondrial DNA Depletion. JIMD Reports, 2015, 27, 1-9.	1.5	19
27	Analysis of <i>DPP6</i> and <i>FGGY</i> as candidate genes for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 389-391.	2.1	18
28	C9orf72 Repeat Expansions in Rapid Eye Movement Sleep Behaviour Disorder. Canadian Journal of Neurological Sciences, 2014, 41, 759-762.	0.5	18
29	A role for ubiquilin 2 mutations in neurodegeneration. Nature Reviews Neurology, 2011, 7, 599-600.	10.1	16
30	Resolution of refractory hypotension and anuria in a premature newborn with lossâ€ofâ€function of ACE. American Journal of Medical Genetics, Part A, 2015, 167, 1654-1658.	1.2	10
31	Mosaic <i>KRAS</i> mutation in a patient with encephalocraniocutaneous lipomatosis and renovascular hypertension. American Journal of Medical Genetics, Part A, 2018, 176, 2523-2527.	1.2	7
32	Genetic Diagnostic Testing for Inherited Cardiomyopathies. Journal of Molecular Diagnostics, 2019, 21, 437-448.	2.8	7
33	Identification of a novel homozygous SPG7 mutation by whole exome sequencing in a Greek family with a complicated form of hereditary spastic paraplegia. European Journal of Medical Genetics, 2015, 58, 573-577.	1.3	6
34	Chromosome 9p21 in amyotrophic lateral sclerosis: the plot thickens. Lancet Neurology, The, 2010, 9, 945-947.	10.2	3
35	Leveraging the power of new molecular technologies in the clinical setting requires unprecedented awareness of limitations and drawbacks: experience of one diagnostic laboratory. Journal of Medical Genetics, 2019, 56, 408-412.	3.2	3
36	Adopting High-Resolution Allele Frequencies Substantially Expedites Variant Interpretation in Genetic Diagnostic Laboratories. Journal of Molecular Diagnostics, 2019, 21, 602-611.	2.8	0